MTORC1/2 Inhibition as a Therapeutic Strategy for PIK3CA Mutant Cancers

Molecular Cancer Therapeutics - United States
doi 10.1158/1535-7163.mct-18-0510
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

mTORC1 Inhibition Is Required for Sensitivity to PI3K P110 Inhibitors in PIK3CA-Mutant Breast Cancer

Science Translational Medicine
Medicine
2013English

Dual Inhibition of PI3K and mTORC1/2 Signaling by NVP-BEZ235 as a New Therapeutic Strategy for Acute Myeloid Leukemia

Clinical Cancer Research
Cancer ResearchOncology
2010English

Substrate-Selective COX-2 Inhibition as a Novel Strategy for Therapeutic Endocannabinoid Augmentation

Trends in Pharmacological Sciences
ToxicologyPharmacology
2014English

DDR1 Inhibition as a New Therapeutic Strategy for Colorectal Cancer

Molecular and Cellular Oncology
Cancer ResearchMolecular Medicine
2018English

Inhibition of the BCR-Abl Tyrosine Kinase as a Therapeutic Strategy for CML

Oncogene
Cancer ResearchGeneticsMolecular Biology
2002English

RAD001 Offers a Therapeutic Intervention Through Inhibition of mTOR as a Potential Strategy for Esophageal Cancer

Oncology Reports
MedicineCancer ResearchOncology
2010English

Inhibition of 12/15-Lipoxygenase as Therapeutic Strategy to Treat Stroke

Annals of Neurology
Neurology
2012English

Combined PPARg Activation and XIAP Inhibition as a Potential Therapeutic Strategy for Ovarian Granulosa Cell Tumors

Molecular Cancer Therapeutics
Cancer ResearchOncology
2018English

A Landscape of Therapeutic Cooperativity in KRAS Mutant Cancers Reveals Principles for Controlling Tumor Evolution

Cell Reports
BiochemistryGeneticsMolecular Biology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy